Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology
February 22 2021 - 8:20AM
InvestorsHub NewsWire
SAN FRANCISCO, CA -- February 22, 2021 -- InvestorsHub
NewsWire -- Oncology Pharma,
Inc. (OTC:
ONPH) is pleased to announce that it has extended a world-wide
Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in
the growing Veterinary Oncology market.
Nanosmart possesses proprietary technology and intellectual
property rights for the development of liposomal and/or
emulsion-based drug formulations that incorporate anti-nuclear
antibodies (ANA).
The global veterinary oncology market size was estimated at USD
199.9 million in 2019 and is anticipated to witness a Compound
Annual Growth Rate (CAGR) of 10.7% over the next decade. A
major driver of the market growth is the increasing prevalence of
cancer in the pet population paired with the rising adoption of
veterinary cancer therapy. Additionally, developed economies
are spending more on animal healthcare due to pet owners’ rising
willingness to spend on pet healthcare and government initiatives
for veterinary cancer treatment.
ANA may be utilized as a targeting agent in pharmaceutical
compounds to deliver active pharmaceutical ingredients to tumor
sites, potentially resulting in safer and more effective cancer
therapies. ANA-conjugated formulations like those licensed
from NanoSmart present an opportunity to deliver better healthcare
options for a growing and receptive market.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTCPK:
ONPH) (the "Company") is currently engaging in research and
development of therapeutics for oncology and prides itself for
having a world-class Advisory Board that keeps the Company in the
forefront of developing technologies in cancer research,
biotechnology, and healthcare.
ABOUT NANOSMART PHARMACEUTICALS, INC.
NanoSmart® Pharmaceuticals is a privately-held California
corporation that is developing nanoparticle drug delivery platforms
that utilize anti-nuclear antibody (ANA) to target existing drug
therapies to areas of necrosis present in virtually all solid
cancer tumors.
FORWARD-LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships; and, costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038 Fax: 415-946-8801
Website: www.oncology-pharma.com
Email: info@oncology-pharma.com
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Sep 2023 to Sep 2024